title: Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance.
abstract: BACKGROUND
  In colorectal surgery UICC/AJCC criteria require a yield of 12 or more locoregional lymph nodes for adequate staging. Neoadjuvant radiochemotherapy for rectal carcinoma reduces the number of lymph nodes in the resection specimen; the prognostic impact of this reduced lymph node yield has not been determined.
  
  
  METHODS
  One hundred two patients with uT3 rectal carcinoma who were receiving neoadjuvant radiochemotherapy were compared with 114 patients with uT3 rectal carcinoma who were receiving primary surgery followed by adjuvant radiochemotherapy. Total lymph node yield and number of tumor-positive lymph nodes were determined and correlated with survival.
  
  
  RESULTS
  After neoadjuvant radiochemotherapy both total lymph node yield (12.9 vs. 21.4, p < 0.0001) and number of tumor-positive lymph nodes (1.0 vs. 2.3, p = 0.014) were significantly lower than after primary surgery plus adjuvant radiochemotherapy. Reduced total lymph node yield in neoadjuvantly treated patients had no prognostic impact, with overall survival of patients with 12 or more lymph nodes the same as that of patients with less than 12 lymph nodes. Overall survival of neoadjuvantly treated patients was significantly influenced by the number of tumor-positive lymph nodes with 5-year-survival rates of 88, 63, and 39% for 0, 1-3, and more than 3 positive lymph nodes (p < 0.0001).
  
  
  CONCLUSIONS
  The UICC/AJCC criterion of a total lymph node yield of 12 or more should be revised for rectal carcinoma patients.
authors.affiliation: Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, 81675, Munich, Germany. ddoll@gmx.de
authors.forename: Dietrich
authors.initials: D
authors.lastname: Doll
authors.forename: Ralf
authors.initials: R
authors.lastname: Gertler
authors.forename: Matthias
authors.initials: M
authors.lastname: Maak
authors.forename: Jan
authors.initials: J
authors.lastname: Friederichs
authors.forename: Karen
authors.initials: K
authors.lastname: Becker
authors.forename: Hans
authors.initials: H
authors.lastname: Geinitz
authors.forename: Monika
authors.initials: M
authors.lastname: Kriner
authors.forename: Hjalmar
authors.initials: H
authors.lastname: Nekarda
authors.forename: Jörg R
authors.initials: JR
authors.lastname: Siewert
authors.forename: Robert
authors.initials: R
authors.lastname: Rosenberg
mesh_terms: D002277:Carcinoma / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D015996:Survival Rate